Interferon-β inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis
M Yu, A Nishiyama, BD Trapp, VK Tuohy - Journal of neuroimmunology, 1996 - Elsevier
The results of two phase III clinical trials have recently shown that interferon-beta (IFN/3) is
effective in the treatment of relapsing-remitting multiple sclerosis (RRMS). Treatment with
IFN/3 results in a significant decrease in the rate of clinical relapse and a marked delay in
progression to disability compared to placebo-treated control patients. In the present study,
we demonstrate similar therapeutic effects after treating (SWR X SJL) F, mice with IFN/3 at
the onset of clinical signs of experimental autoimmune encephalomyelitis (EAE), a disease …
effective in the treatment of relapsing-remitting multiple sclerosis (RRMS). Treatment with
IFN/3 results in a significant decrease in the rate of clinical relapse and a marked delay in
progression to disability compared to placebo-treated control patients. In the present study,
we demonstrate similar therapeutic effects after treating (SWR X SJL) F, mice with IFN/3 at
the onset of clinical signs of experimental autoimmune encephalomyelitis (EAE), a disease …